GPP
NVLN

Great Point Partners’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Great Point Partners’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-2,500
Closed -$9K – 47
2018
Q2 		$9K Buy
+2,500
New +$10K ﹤0.01% 38

Other funds holding NVLN

EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Great Point Partners's NVLN Position: Q3 2018 in Review

Great Point Partners sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q3 2018, closing a stake of 2,500 shares — an estimated $9K sold.

Great Point Partners first reported a position in NVLN in Q2 2018 and held it in 1 quarter. The position peaked at $9K in Q2 2018. 49 funds tracked by Wall St. Rank hold NVLN as of Q3 2018.

  • Great Point Partners reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q3 2018 after selling out during the quarter.
  • Great Point Partners sold 2,500 Novelion Therapeutics Inc. Common Shares shares in Q3 2018, an estimated $9K.
  • Great Point Partners first reported a position in Novelion Therapeutics Inc. Common Shares in Q2 2018 and held it in 1 quarter.
  • Great Point Partners's Novelion Therapeutics Inc. Common Shares position peaked at $9K in Q2 2018.
  • 49 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q3 2018.

Based on Great Point Partners's 13F filing for Q3 2018, filed 14 Nov 2018.